Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Hemoglobinopathies Market The hemoglobinopathies market is advancing rapidly, driven by gene therapy, new drugs, and rising access for trea ...

Cost-effectiveness agency NICE has issued final draft guidance on Oxbryta (voxelotor) that clears the way for the use of the drug – with or without hydroxycarbamide – as an option for treating ...

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.

Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer 's (PFE -0.17%) share price has declined during the ...

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.

The Sickle Cell Disease Treatment Market is expected to reach at a CAGR of 15.8% during the forecast period 2025-2033. The Sickle Cell Disease Treatment Market is growing due to rising disease ...

Pfizer has experienced disappointing product and pipeline setbacks as well. It withdrew sickle cell disease therapy Oxbryta from the market last year after concluding that the benefits no longer ...